StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

Earnings

Ultragenyx Pharmaceutical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$173.00M
+8.1% on a year earlier
EPS, Q3 FY2026
-$1.16
-$1.81 a year earlier
Latest guidance
Raised
Nov 3, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Ultragenyx Pharmaceutical's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close$173.00M+8.1%-$1.16Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026after the close$214.00M+28.9%-$0.90Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$136.00M-2.2%-$1.84Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026after the close$207.00M+25.5%-$1.29Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025after the close$160.00M+15.1%-$1.81Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$166.00M+12.9%-$1.17Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$139.00M+27.5%–Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025after the close$165.00M+29.9%-$1.39Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024after the close$139.00M+41.7%–Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024after the close$147.00M+35.7%-$1.52Release
Q1 FY2024ended Mar 31, 2024May 2, 2024after the close$109.00M+8.5%-$2.03Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Ultragenyx Pharmaceutical's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Dojolvi revenueFY2026$100.00M – $110.00M$100.00M – $110.00MLoweredNov 3, 2026
Dojolvi revenueFY2026$100.00M – $110.00M$100.00M – $110.00MLoweredAug 4, 2026

Guidance vs results

The last range Ultragenyx Pharmaceutical gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$640.00M – $670.00M$672.00MΣ4QAbove range

Guidance history

Every forecast Ultragenyx Pharmaceutical put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026Dojolvi revenueFY2026$100.00M – $110.00MLowered
Nov 3, 2026Crysvita revenueFY2026$500.00M – $520.00MLowered
Nov 3, 2026total revenueFY2026$730.00M – $760.00MRaised
Aug 4, 2026Dojolvi revenueFY2026$100.00M – $110.00MLowered
Aug 4, 2026Crysvita revenueFY2026$500.00M – $520.00MLowered
Aug 4, 2026total revenueFY2026$730.00M – $760.00MRaised
May 5, 2026Dojolvi revenueFY2026$100.00M – $110.00MLowered
May 5, 2026Crysvita revenueFY2026$500.00M – $520.00MLowered
May 5, 2026total revenueFY2026$730.00M – $760.00MNew
Feb 12, 2026Dojolvi revenueFY2026$100.00M – $110.00MLowered
Feb 12, 2026Crysvita revenueFY2026$500.00M – $520.00MLowered
Feb 12, 2026Total revenues, excluding potential revenue from new product launchesFY2026$730.00M – $760.00MNew
Nov 4, 2025Crysvita revenueFY2025$460.00M – $480.00MNew
Nov 4, 2025Dojolvi revenueFY2025$90.00M – $100.00MLowered
Nov 4, 2025Total revenueFY2025$640.00M – $670.00MNew
Aug 5, 2025Total revenuesFY2025+14% – +20%Reaffirmed
Aug 5, 2025Total revenueFY2025$640.00M – $670.00MRaised
Aug 5, 2025Crysvita revenueFY2025$460.00M – $480.00MLowered
Aug 5, 2025Dojolvi revenueFY2025$90.00M – $100.00MLowered
May 6, 2025RevenuesFY2025+14% – +20%Reaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Ultragenyx Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?